CN102884084B - 抗her2抗体及组合物 - Google Patents
抗her2抗体及组合物 Download PDFInfo
- Publication number
- CN102884084B CN102884084B CN201180022307.6A CN201180022307A CN102884084B CN 102884084 B CN102884084 B CN 102884084B CN 201180022307 A CN201180022307 A CN 201180022307A CN 102884084 B CN102884084 B CN 102884084B
- Authority
- CN
- China
- Prior art keywords
- antibody
- sequence
- heavy chain
- light
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31055210P | 2010-03-04 | 2010-03-04 | |
DKPA201070085 | 2010-03-04 | ||
US61/310,552 | 2010-03-04 | ||
DKPA201070085 | 2010-03-04 | ||
US35413310P | 2010-06-11 | 2010-06-11 | |
US61/354,133 | 2010-06-11 | ||
US201061428014P | 2010-12-29 | 2010-12-29 | |
US61/428,014 | 2010-12-29 | ||
PCT/IB2011/050903 WO2011107957A1 (en) | 2010-03-04 | 2011-03-03 | Anti-her2 antibodies and compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102884084A CN102884084A (zh) | 2013-01-16 |
CN102884084B true CN102884084B (zh) | 2016-12-07 |
Family
ID=44541704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180022307.6A Expired - Fee Related CN102884084B (zh) | 2010-03-04 | 2011-03-03 | 抗her2抗体及组合物 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2542589A4 (he) |
JP (1) | JP6039428B2 (he) |
CN (1) | CN102884084B (he) |
TW (1) | TW201141519A (he) |
WO (1) | WO2011107957A1 (he) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2337800B1 (en) | 2008-09-15 | 2013-10-02 | Yeda Research and Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
DK2635604T3 (en) * | 2010-11-01 | 2017-02-27 | Symphogen As | PAN-HER-ANTIBODY COMPOSITION |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
US9040047B2 (en) | 2011-05-16 | 2015-05-26 | Yeda Research And Development Co. Ltd. | Combinations of anti ErbB antibodies for the treatment of cancer |
KR101933990B1 (ko) | 2012-05-02 | 2018-12-31 | 심포젠 에이/에스 | 인간화 panher 항체 조성물 |
PT2888283T (pt) | 2012-08-24 | 2018-11-16 | Univ California | Anticorpos e vacinas para serem utilizados no tratamento de cancros que expressam ror1 e inibição de metástases |
CN109320612B (zh) | 2013-11-19 | 2020-10-27 | 荣昌生物制药(烟台)有限公司 | 抗her2抗体及其缀合物 |
CN104974261B (zh) * | 2014-04-01 | 2019-06-14 | 三生国健药业(上海)股份有限公司 | 重组抗her2/ps双特异性抗体、其制备方法和应用 |
CA2966551A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Assay and method for determining cdc eliciting antibodies |
CN106831987B (zh) * | 2015-12-04 | 2020-01-21 | 浙江大学 | 一种抗人her2抗体及其编码基因和应用 |
CN109154600A (zh) * | 2016-06-16 | 2019-01-04 | 豪夫迈·罗氏有限公司 | 用于确定cdc诱导抗体的测定法和方法 |
KR20230047507A (ko) | 2016-06-27 | 2023-04-07 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
CN107137424A (zh) * | 2017-05-15 | 2017-09-08 | 广州领晟医疗科技有限公司 | 一种利用正常小鼠建立her2阳性肿瘤的动物模型的方法 |
RS64690B1 (sr) * | 2018-03-13 | 2023-11-30 | Zymeworks Bc Inc | Konjugati biparatopskog anti-her2 antitela i leka i postupci za njihovu upotrebu |
CN109134656A (zh) * | 2018-09-12 | 2019-01-04 | 四川妙和生物科技有限公司 | 一种抗her2多克隆抗体 |
CN113646332A (zh) * | 2019-03-15 | 2021-11-12 | 公益财团法人癌研究会 | 抗平足蛋白抗体 |
EP3941947A4 (en) * | 2019-03-22 | 2022-12-14 | Olivia Newton-John Cancer Research Institute | ANTI-HER2 BINDING MOLECULES |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999055367A1 (en) * | 1998-04-24 | 1999-11-04 | The Regents Of The University Of California | INTERNALIZING ErbB2 ANTIBODIES |
WO2006087637A2 (en) * | 2005-02-21 | 2006-08-24 | Hellenic Pasteur Institute | Anti her2/neu antibody |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6794128B2 (en) * | 1998-04-24 | 2004-09-21 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
JP2006516117A (ja) * | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ErbB2抗体を用いた非悪性疾病または疾患の治療 |
US7498142B2 (en) * | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
KR101706255B1 (ko) * | 2008-08-29 | 2017-02-14 | 심포젠 에이/에스 | 재조합 항-표피 성장 인자 수용체 항체 조성물 |
-
2011
- 2011-03-03 TW TW100107086A patent/TW201141519A/zh unknown
- 2011-03-03 WO PCT/IB2011/050903 patent/WO2011107957A1/en active Application Filing
- 2011-03-03 CN CN201180022307.6A patent/CN102884084B/zh not_active Expired - Fee Related
- 2011-03-03 EP EP11750275.7A patent/EP2542589A4/en not_active Withdrawn
- 2011-03-03 JP JP2012555532A patent/JP6039428B2/ja not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999055367A1 (en) * | 1998-04-24 | 1999-11-04 | The Regents Of The University Of California | INTERNALIZING ErbB2 ANTIBODIES |
WO2006087637A2 (en) * | 2005-02-21 | 2006-08-24 | Hellenic Pasteur Institute | Anti her2/neu antibody |
Non-Patent Citations (1)
Title |
---|
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells;Rita Nahta,et al.;《Cancer Research》;20040401;第64卷(第7期);摘要和第2343页左栏第2-3段,第2344页右栏最后1段 * |
Also Published As
Publication number | Publication date |
---|---|
JP6039428B2 (ja) | 2016-12-07 |
EP2542589A1 (en) | 2013-01-09 |
TW201141519A (en) | 2011-12-01 |
WO2011107957A1 (en) | 2011-09-09 |
EP2542589A4 (en) | 2013-08-07 |
JP2013520984A (ja) | 2013-06-10 |
CN102884084A (zh) | 2013-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102884084B (zh) | 抗her2抗体及组合物 | |
US10221246B2 (en) | Pan-HER antibody composition | |
US9217039B2 (en) | Anti-HER3 antibodies and compositions | |
JP6325527B2 (ja) | ヒト化pan−her抗体組成物 | |
CN104093743B (zh) | 特异于her3的结合分子及其用途 | |
US8609095B2 (en) | Anti-HER2 antibodies and compositions | |
CN105884900A (zh) | 单特异性和双特异性抗igf-1r和抗erbb3抗体 | |
CN107708666A (zh) | 治疗癌症的联合疗法 | |
JP2020515594A (ja) | Erbb−2、erbb−2/erbb−3陽性腫瘍を有する個体の処置のための、erb−2及びerbb−3の細胞外部分上のエピトープに結合する抗原結合部位を含むerbb−2標的化剤及び二重特異性抗体 | |
JP2016182135A (ja) | 抗her2抗体および組成物 | |
BR112013010764A2 (pt) | composição de anticorpos anti-her3, molécula de ligação biespecífica, molécula de ácido nucleico, vetor de expressão, linhagem celular policlonal, método para produção da referida composição, composição farmacêutica e uso da referida composição | |
BR112013010718A2 (pt) | composição de anticorpo pan-her, composição farmacêutica, método para produção e uso da referida composição |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161207 Termination date: 20200303 |
|
CF01 | Termination of patent right due to non-payment of annual fee |